Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers

BMC Cancer

Hazem Ghebeh³  Ghida Majed Sleiman⁵  Pulicat S Manogaran⁵  Amer Al-Mazrou⁵  Eman Barhoush⁵  Falah H Al-Mohanna⁶  Asma Tulbah²  Khalid Al-Faqeeh¹  Chaker N Adra⁴ 

[1] Stem Cell & Tissue Re-engineering Program, Department of Surgery, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

[2] Stem Cell & Tissue Re-engineering Program, Departments of Pathology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

[3] College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia

[4] Stem Cell & Tissue Re-engineering Program, Research Centre, King Faisal Specialist Hospital and Research Centre, PO Box 3354, Riyadh, (MBC 03), 11211, Kingdom of Saudi Arabia

[5] Stem Cell & Tissue Re-engineering Program, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

[6] Stem Cell & Tissue Re-engineering Program, Departments of Comparative Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

关键词: Mammary gland;    MUC-1;    CD44^high/CD24^low;    ALDH;    CD10;    Flow cytometry;    Breast cancer;    Stem cells;    Normal breast;   

Others  :  1079701
DOI  :  10.1186/1471-2407-13-289

 received in 2013-03-17, accepted in 2013-06-04,  发布年份 2013

【 摘 要 】

Background

Accumulating evidence supports cancer to initiate and develop from a small population of stem-like cells termed as cancer stem cells (CSC). The exact phenotype of CSC and their counterparts in normal mammary gland is not well characterized. In this study our aim was to evaluate the phenotype and function of stem/progenitor cells in normal mammary epithelial cell populations and their malignant counterparts.

Methods

Freshly isolated cells from both normal and malignant human breasts were sorted using 13 widely used stem/progenitor cell markers individually or in combination by multi-parametric (up to 9 colors) cell sorting. The sorted populations were functionally evaluated by their ability to form colonies and mammospheres, in vitro.

Results

We have compared, for the first time, the stem/progenitor markers of normal and malignant breasts side-by-side. Amongst all markers tested, we found CD44^high/CD24^low cell surface marker combination to be the most efficient at selecting normal epithelial progenitors. Further fractionation of CD44^high/CD24^low positive cells showed that this phenotype selects for luminal progenitors within Ep-CAM^high/CD49f + cells, and enriches for basal progenitors within Ep-CAM^-/low/CD49f + cells. On the other hand, primary breast cancer samples, which were mainly luminal Ep-CAM^high, had CD44^high/CD24^low cells among both CD49f^neg and CD49f + cancer cell fractions. However, functionally, CSC were predominantly CD49f + proposing the use of CD44^high/CD24^low in combination with Ep-CAM/CD49f cell surface markers to further enrich for CSC.

Conclusion

Our study clearly demonstrates that both normal and malignant breast cells with the CD44^high/CD24^low phenotype have the highest stem/progenitor cell ability when used in combination with Ep-CAM/CD49f reference markers. We believe that this extensive characterization study will help in understanding breast cancer carcinogenesis, heterogeneity and drug resistance.

【 授权许可】

   
2013 Ghebeh et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH: ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Canc Res 2005, 65(10):4320-4333.
• [2]Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al.: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Canc Inst 2008, 100(9):672-679.
• [3]Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760.
• [4]Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Canc 2008, 8(10):755-768.
• [5]Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988.
• [6]Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-567.
• [7]Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, Caron de Fromentel C, Maguer-Satta V: The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010, 28(6):1081-1088. http://www.ncbi.nlm.nih.gov/pubmed/20506111 webcite
• [8]Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT, Eaves CJ: A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 2008, 14(12):1384-1389.
• [9]Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17(10):1253-1270.
• [10]Stingl J, Raouf A, Emerman JT, Eaves CJ: Epithelial progenitors in the normal human mammary gland. J Mammary Gland Biol Neoplasia 2005, 10(1):49-59.
• [11]Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, et al.: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15(8):907-913.
• [12]Alexander CM, Puchalski J, Klos KS, Badders N, Ailles L, Kim CF, Dirks P, Smalley MJ: Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell 2009, 5(6):579-583.
• [13]Fillmore CM, Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Canc Res 2008, 10(2):R25. BioMed Central Full Text
• [14]Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, et al.: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006, 8(3):190-198.
• [15]Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Canc 2007, 121(4):751-758.
• [16]Wang CS, Goulet F, Lavoie J, Drouin R, Auger F, Champetier S, Germain L, Tetu B: Establishment and characterization of a new cell line derived from a human primary breast carcinoma. Canc Genet Cytogenet 2000, 120(1):58-72.
• [17]Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Canc Res 1997, 57(22):4987-4991.
• [18]Stingl J: Detection and analysis of mammary gland stem cells. J Pathol 2009, 217(2):229-241.
• [19]Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, Caron De Fromentel C, Maguer-Satta V: The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010, 28(6):1081-1088.
• [20]Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al.: Molecular definition of breast tumor heterogeneity. Canc Cell 2007, 11(3):259-273.
• [21]Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H: Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Canc Res 2005, 11(3):1154-1159.
• [22]Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L: The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008, 39(7):1096-1102.
• [23]Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO: A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Canc Res Treat 2012, 133(3):979-995.
• [24]Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, Purushotham AD: Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Canc 2008, 122(2):298-304.
• [25]Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C: Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Canc Res 2011, 13(6):R118. BioMed Central Full Text
• [26]Shehata M, Teschendorff A, Sharp G, Novcic N, Russell IA, Avril S, Prater M, Eirew P, Caldas C, Watson CJ: Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Canc Res 2012, 14(5):R134. BioMed Central Full Text
• [27]Gusterson BA, Warburton MJ, Mitchell D, Ellison M, Neville AM, Rudland PS: Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Canc Res 1982, 42(11):4763-4770.
• [28]Kalof AN, Tam D, Beatty B, Cooper K: Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol 2004, 57(6):625-629.
• [29]Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA: Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Canc Cell 2007, 12(2):160-170.
• [30]Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, et al.: Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 2012, 109(8):2772-2777.
• [31]Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, et al.: BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7(3):403-417.
• [32]Lo PK, Kanojia D, Liu X, Singh UP, Berger FG, Wang Q, Chen H: CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 2012, 31(21):2614-2626.
• [33]Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle RJ, Boecker W: Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999, 34(1):25-34.
• [34]Fillmore C, Kuperwasser C: Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Canc Res 2007, 9(3):303. BioMed Central Full Text